365996-66-3

Basic information

• Product Name: 4H-Pyrrolo[3,4-d]thiazole,5,6-dihydro-5-methyl-(9CI)
• Synonyms: 4H-Pyrrolo[3,4-d]thiazole,5,6-dihydro-5-methyl-(9CI);5-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole;5-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazole
• CAS NO: 365996-66-3
• Molecular Formula: C6H8N2S
• Molecular Weight: 140.20612
• Product Categories: AMINETERTIARY
• Mol File: 365996-66-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4H-Pyrrolo[3,4-d]thiazole,5,6-dihydro-5-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrrolo[3,4-d]thiazole,5,6-dihydro-5-methyl-(9CI)(365996-66-3)
• EPA Substance Registry System: 4H-Pyrrolo[3,4-d]thiazole,5,6-dihydro-5-methyl-(9CI)(365996-66-3)

Safety Data

• Hazardous Substances Data: 365996-66-3(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 365996-65-2 5,6-dihydro-4H-pyrrolo[3,4-d]thiazole dihydrobromide 
• 365996-65-2 4,6-dihydro-5H-pyrrolo[3,4-d]thiazole hydrobromide 

Relevant articles and documents

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: Exploration of 6-6 fused rings as alternative S1 moieties

A series of cis-1,2-diaminocyclohexane derivatives possessing a 6-6 fused ring for the S1 moiety were synthesized as novel factor Xa (fXa) inhibitors. The synthesis, structure-activity relationship (SAR), and physicochemical properties are reported herein, together with the discovery of compound 45c, which has potent anti-fXa activity, good physicochemical properties and pharmacokinetic (PK) profiles, including a reduced negative food effect.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.